Clinical trials: Vascular Thrombosis
Venous Thrombosis
A Comparison of the Effects of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression on Blood Flow in the Lower Limb
Deep Vein Thrombosis (DVT) is a life threatening condition and a serious concern among hospitalized patients, with death occurring in approximately 6% of cases.
- Trial name
- NCT01894997
- Testing
- Neuromuscular electrical stimulator, AV Impulse System Model 6000
- Where
- Ireland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National University of Ireland, Galway, Ireland
Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Trial name
- XVU-Phase 1 (NCT00676520)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- United States
- Volunteers
- 8,053 people
- Sponsor
- Abbott Medical Devices
Coronary Disease, Coronary Artery Disease
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT II (NCT00180310)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily
Venous Thromboembolism, Lung Neoplasms
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
After any surgery, there is a risk of venous thromboembolism (VTE), including Deep Vein Thrombosis (DVT) in the major veins of the legs and Pulmonary Embolus (PE) in the lungs.
- Conditions
- Venous Thromboembolism, Lung Neoplasms, Pulmonary Embolism
- Trial name
- NCT02334007
- Testing
- LMWH: Dalteparin
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- McMaster University
Cerebral Venous Thrombosis
Study of Rivaroxaban for CeREbral Venous Thrombosis
SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.
- Trial name
- SECRET (NCT03178864)
- Testing
- Rivaroxaban, Standard of care
- Where
- 11 sites in Canada
- Volunteers
- 55 people
- Sponsor
- University of British Columbia
Deep Vein Thrombosis
PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis
Patients with iliofemoral vein thrombosis are prone to developing post-thrombotic syndrome (PTS). The profunda femoris vein (PFV) is an important inflow of the iliofemoral vein.
- Trial name
- NCT07622199
- Testing
- Endovascular treatment with profunda femoris vein thrombosis clearance (Endovascular treatment with PFV-TC), Percutaneous mechanical thrombectomy without profunda femoris vein thrombosis clearance (PMT without PFV-TC)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- RenJi Hospital
Anti-coagulation Therapy, DVT
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
The WARFARIN Study is a clinical trial designed to determine if the use of genetic information related to warfarin sensitivity can help create a dose of warfarin that will result in less hospitalizations and deaths related to…
- Conditions
- Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple
- Trial name
- WARFARIN (NCT01305148)
- Testing
- Warfarin GenoSTAT Test
- Where
- 56 sites in United States
- Volunteers
- 3,800 people
- Sponsor
- Iverson Genetic Diagnostics, Inc.
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined…
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Trial name
- Quell (NCT07456826)
- Testing
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Harrow Inc
DME, Retinal Vein Occlusion (RVO)
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases.
- Conditions
- DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration
- Trial name
- NCT07328776
- Testing
- QiLin-assisted, physician only, without QiLin assisted
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Dissection, Aortic
sirA-CPB Strategy Reduces New Ischemic/Embolic Lesions After Acute Type A Aortic Dissection Surgery
Type A acute aortic dissection (TAAAD) is a life-threatening disease that typically requires emergency surgery to prevent rupture from causing major bleeding events, with insufficient attention paid to its thromboembolic events.
- Trial name
- NCT07750548
- Testing
- sirA-CPB strategy, the traditional CPB strategy
- Volunteers
- 270 people
- Sponsor
- Xiangya Hospital of Central South University
Pulmonary Edema, Pneumonia
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second.
- Conditions
- Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion
- Trial name
- NCT06538376
- Testing
- Portable Dynamic Digital Radiography (DDR)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Brigham and Women's Hospital
Thromboembolism, Anticoagulant-induced Bleeding
Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement
The goal of the study is to evaluate the frequency of cardiovascular and thromboembolic complications in patients with cardiovascular disease after lower limb joint replacement, the influence of known risk factors and strategies…
- Trial name
- NCT06627933
- Testing
- No intervention
- Where
- Russia
- Volunteers
- 1,733 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Venous Thromboembolism, Venous Thromboses
Leiden Thrombosis Recurrence Risk Prevention
The goal of this clinical trial is to evaluate tailored duration of long-term anticoagulant treatment after a first venous thromboembolism based on individualized risk assessments of recurrent VTE and major bleeding risks.
- Conditions
- Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- L-TRRiP (NCT06087952)
- Testing
- Randomised treatment advice (discontinue vs continue after 3 months), VTE-BLEED score, L-TRRiP score
- Where
- 19 sites in Netherlands
- Volunteers
- 608 people
- Sponsor
- Leiden University Medical Center
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Traumatic Intracranial Haemorrhage
OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)
Victims of trauma with severe head injury who have bled into their brains are at high risk of developing blood clots in their legs. These blood clots can break off and travel through the bloodstream to the lungs causing death.
- Trial name
- OPTTTICH (NCT01589393)
- Testing
- Enoxaparin
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- McMaster University
Venous Thromboembolism
Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism
The aim of the study is to investigate the existence of clonal hematopoiesis of indeterminate potential (CHIP) in patients with a history of venous thromboembolism.
- Trial name
- CHIPS (NCT04477564)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Coronary Artery Disease
Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions
The primary objective of Infinnium-Core™ Registry is to assess the safety and efficacy of the Infinnium-Core™ Paclitaxel Eluting Coronary Stent System in de novo Coronary Lesions.
- Trial name
- NCT00936780
- Testing
- Infinnium-Core™ Paclitaxel eluting Coronary Stent
- Where
- 7 sites in India
- Volunteers
- 67 people
- Sponsor
- Sahajanand Medical Technologies Limited
Achilles Tendon Rupture, Deep Venous Thrombosis
Early Mobilization After Achilles Tendon Rupture
The purpose of this study is to determine whether early mobilization after Achilles tendon rupture can speed up healing, prevent development of venous thromboembolism and improve patient outcome.
- Trial name
- EarlyM-Achil (NCT02318472)
- Testing
- VACOped orthosis, Plaster cast
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Karolinska University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.